These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

967 related items for PubMed ID: 20156091

  • 1. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF, AI266073 Study Group.
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [Abstract] [Full Text] [Related]

  • 2. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A, AI266073 Study Group.
    J Acquir Immune Defic Syndr; 2009 Jun 01; 51(2):163-74. PubMed ID: 19357529
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, Ramanathan S, Wang MH, White K, Chuck SK, Cheng AK.
    HIV Clin Trials; 2013 Jun 01; 14(5):216-23. PubMed ID: 24144898
    [Abstract] [Full Text] [Related]

  • 4. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.
    AIDS Patient Care STDS; 2014 Apr 01; 28(4):168-75. PubMed ID: 24660840
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S, Flandre P, Nguyen N, De Castro N, Molina JM, Delaugerre C.
    J Med Virol; 2015 Feb 01; 87(2):187-91. PubMed ID: 25070158
    [Abstract] [Full Text] [Related]

  • 6. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.
    HIV Clin Trials; 2013 Feb 01; 14(3):81-91. PubMed ID: 23835510
    [Abstract] [Full Text] [Related]

  • 7. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    HIV Clin Trials; 2015 Feb 01; 16(1):30-8. PubMed ID: 25777187
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.
    AIDS; 2011 Mar 27; 25(6):F7-12. PubMed ID: 21412057
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
    Pujari S, Dravid A, Gupte N, Joshi K, Bele V.
    Medscape J Med; 2008 Mar 27; 10(8):196. PubMed ID: 18924648
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.